The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Urinary System Drugs Market Research Report 2024
Synopsis
The global Urinary System Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Urinary System Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urinary System Drugs.
Report Scope
The Urinary System Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Urinary System Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Urinary System Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Bayer
Pfizer
GSK
Boehringer Ingelheim
Roche
Novartis
AstraZeneca
Dr. Reddy’s Laboratories
Mylan
Sun Pharma
Cipla
Merck
Cubist Pharmaceuticals
Abbott Laboratories
Eli Lilly
Melinta Therapeutics
Sanofi
Daiichi Sankyo
Lupin
Apogepha
Astellas Pharma
Dr. Dunner
Kowa
Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
Tianjin Tongrentang Group
Jiangsu Hengrui Pharmaceutical
Hunan Qianjin Xiang River Pharmaceutical
Kunming Jida Pharmaceutical
Jiangsu Lianhuan Pharmaceutical
Segment by Type
Injection
Tablets
Capsule
Suppository
Granules
Powder
Pills
Cream
Others
Segment by Application
Kidney Disease Medication
Medication For Prostate Disease
Male Dysfunction
Lithotripsy Drug
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urinary System Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Urinary System Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Urinary System Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urinary System Drugs.
Report Scope
The Urinary System Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Urinary System Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Urinary System Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Bayer
Pfizer
GSK
Boehringer Ingelheim
Roche
Novartis
AstraZeneca
Dr. Reddy’s Laboratories
Mylan
Sun Pharma
Cipla
Merck
Cubist Pharmaceuticals
Abbott Laboratories
Eli Lilly
Melinta Therapeutics
Sanofi
Daiichi Sankyo
Lupin
Apogepha
Astellas Pharma
Dr. Dunner
Kowa
Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
Tianjin Tongrentang Group
Jiangsu Hengrui Pharmaceutical
Hunan Qianjin Xiang River Pharmaceutical
Kunming Jida Pharmaceutical
Jiangsu Lianhuan Pharmaceutical
Segment by Type
Injection
Tablets
Capsule
Suppository
Granules
Powder
Pills
Cream
Others
Segment by Application
Kidney Disease Medication
Medication For Prostate Disease
Male Dysfunction
Lithotripsy Drug
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urinary System Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Urinary System Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Injection
1.2.3 Tablets
1.2.4 Capsule
1.2.5 Suppository
1.2.6 Granules
1.2.7 Powder
1.2.8 Pills
1.2.9 Cream
1.2.10 Others
1.3 Market by Application
1.3.1 Global Urinary System Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Kidney Disease Medication
1.3.3 Medication For Prostate Disease
1.3.4 Male Dysfunction
1.3.5 Lithotripsy Drug
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Urinary System Drugs Market Perspective (2019-2030)
2.2 Urinary System Drugs Growth Trends by Region
2.2.1 Global Urinary System Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Urinary System Drugs Historic Market Size by Region (2019-2024)
2.2.3 Urinary System Drugs Forecasted Market Size by Region (2025-2030)
2.3 Urinary System Drugs Market Dynamics
2.3.1 Urinary System Drugs Industry Trends
2.3.2 Urinary System Drugs Market Drivers
2.3.3 Urinary System Drugs Market Challenges
2.3.4 Urinary System Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Urinary System Drugs Players by Revenue
3.1.1 Global Top Urinary System Drugs Players by Revenue (2019-2024)
3.1.2 Global Urinary System Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Urinary System Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Urinary System Drugs Revenue
3.4 Global Urinary System Drugs Market Concentration Ratio
3.4.1 Global Urinary System Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Urinary System Drugs Revenue in 2023
3.5 Urinary System Drugs Key Players Head office and Area Served
3.6 Key Players Urinary System Drugs Product Solution and Service
3.7 Date of Enter into Urinary System Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Urinary System Drugs Breakdown Data by Type
4.1 Global Urinary System Drugs Historic Market Size by Type (2019-2024)
4.2 Global Urinary System Drugs Forecasted Market Size by Type (2025-2030)
5 Urinary System Drugs Breakdown Data by Application
5.1 Global Urinary System Drugs Historic Market Size by Application (2019-2024)
5.2 Global Urinary System Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Urinary System Drugs Market Size (2019-2030)
6.2 North America Urinary System Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Urinary System Drugs Market Size by Country (2019-2024)
6.4 North America Urinary System Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Urinary System Drugs Market Size (2019-2030)
7.2 Europe Urinary System Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Urinary System Drugs Market Size by Country (2019-2024)
7.4 Europe Urinary System Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Urinary System Drugs Market Size (2019-2030)
8.2 Asia-Pacific Urinary System Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Urinary System Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Urinary System Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Urinary System Drugs Market Size (2019-2030)
9.2 Latin America Urinary System Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Urinary System Drugs Market Size by Country (2019-2024)
9.4 Latin America Urinary System Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Urinary System Drugs Market Size (2019-2030)
10.2 Middle East & Africa Urinary System Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Urinary System Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Urinary System Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Urinary System Drugs Introduction
11.1.4 Johnson & Johnson Revenue in Urinary System Drugs Business (2019-2024)
11.1.5 Johnson & Johnson Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Urinary System Drugs Introduction
11.2.4 Bayer Revenue in Urinary System Drugs Business (2019-2024)
11.2.5 Bayer Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Urinary System Drugs Introduction
11.3.4 Pfizer Revenue in Urinary System Drugs Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 GSK
11.4.1 GSK Company Detail
11.4.2 GSK Business Overview
11.4.3 GSK Urinary System Drugs Introduction
11.4.4 GSK Revenue in Urinary System Drugs Business (2019-2024)
11.4.5 GSK Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Detail
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Urinary System Drugs Introduction
11.5.4 Boehringer Ingelheim Revenue in Urinary System Drugs Business (2019-2024)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Urinary System Drugs Introduction
11.6.4 Roche Revenue in Urinary System Drugs Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Urinary System Drugs Introduction
11.7.4 Novartis Revenue in Urinary System Drugs Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Urinary System Drugs Introduction
11.8.4 AstraZeneca Revenue in Urinary System Drugs Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 Dr. Reddy’s Laboratories
11.9.1 Dr. Reddy’s Laboratories Company Detail
11.9.2 Dr. Reddy’s Laboratories Business Overview
11.9.3 Dr. Reddy’s Laboratories Urinary System Drugs Introduction
11.9.4 Dr. Reddy’s Laboratories Revenue in Urinary System Drugs Business (2019-2024)
11.9.5 Dr. Reddy’s Laboratories Recent Development
11.10 Mylan
11.10.1 Mylan Company Detail
11.10.2 Mylan Business Overview
11.10.3 Mylan Urinary System Drugs Introduction
11.10.4 Mylan Revenue in Urinary System Drugs Business (2019-2024)
11.10.5 Mylan Recent Development
11.11 Sun Pharma
11.11.1 Sun Pharma Company Detail
11.11.2 Sun Pharma Business Overview
11.11.3 Sun Pharma Urinary System Drugs Introduction
11.11.4 Sun Pharma Revenue in Urinary System Drugs Business (2019-2024)
11.11.5 Sun Pharma Recent Development
11.12 Cipla
11.12.1 Cipla Company Detail
11.12.2 Cipla Business Overview
11.12.3 Cipla Urinary System Drugs Introduction
11.12.4 Cipla Revenue in Urinary System Drugs Business (2019-2024)
11.12.5 Cipla Recent Development
11.13 Merck
11.13.1 Merck Company Detail
11.13.2 Merck Business Overview
11.13.3 Merck Urinary System Drugs Introduction
11.13.4 Merck Revenue in Urinary System Drugs Business (2019-2024)
11.13.5 Merck Recent Development
11.14 Cubist Pharmaceuticals
11.14.1 Cubist Pharmaceuticals Company Detail
11.14.2 Cubist Pharmaceuticals Business Overview
11.14.3 Cubist Pharmaceuticals Urinary System Drugs Introduction
11.14.4 Cubist Pharmaceuticals Revenue in Urinary System Drugs Business (2019-2024)
11.14.5 Cubist Pharmaceuticals Recent Development
11.15 Abbott Laboratories
11.15.1 Abbott Laboratories Company Detail
11.15.2 Abbott Laboratories Business Overview
11.15.3 Abbott Laboratories Urinary System Drugs Introduction
11.15.4 Abbott Laboratories Revenue in Urinary System Drugs Business (2019-2024)
11.15.5 Abbott Laboratories Recent Development
11.16 Eli Lilly
11.16.1 Eli Lilly Company Detail
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Urinary System Drugs Introduction
11.16.4 Eli Lilly Revenue in Urinary System Drugs Business (2019-2024)
11.16.5 Eli Lilly Recent Development
11.17 Melinta Therapeutics
11.17.1 Melinta Therapeutics Company Detail
11.17.2 Melinta Therapeutics Business Overview
11.17.3 Melinta Therapeutics Urinary System Drugs Introduction
11.17.4 Melinta Therapeutics Revenue in Urinary System Drugs Business (2019-2024)
11.17.5 Melinta Therapeutics Recent Development
11.18 Sanofi
11.18.1 Sanofi Company Detail
11.18.2 Sanofi Business Overview
11.18.3 Sanofi Urinary System Drugs Introduction
11.18.4 Sanofi Revenue in Urinary System Drugs Business (2019-2024)
11.18.5 Sanofi Recent Development
11.19 Daiichi Sankyo
11.19.1 Daiichi Sankyo Company Detail
11.19.2 Daiichi Sankyo Business Overview
11.19.3 Daiichi Sankyo Urinary System Drugs Introduction
11.19.4 Daiichi Sankyo Revenue in Urinary System Drugs Business (2019-2024)
11.19.5 Daiichi Sankyo Recent Development
11.20 Lupin
11.20.1 Lupin Company Detail
11.20.2 Lupin Business Overview
11.20.3 Lupin Urinary System Drugs Introduction
11.20.4 Lupin Revenue in Urinary System Drugs Business (2019-2024)
11.20.5 Lupin Recent Development
11.21 Apogepha
11.21.1 Apogepha Company Detail
11.21.2 Apogepha Business Overview
11.21.3 Apogepha Urinary System Drugs Introduction
11.21.4 Apogepha Revenue in Urinary System Drugs Business (2019-2024)
11.21.5 Apogepha Recent Development
11.22 Astellas Pharma
11.22.1 Astellas Pharma Company Detail
11.22.2 Astellas Pharma Business Overview
11.22.3 Astellas Pharma Urinary System Drugs Introduction
11.22.4 Astellas Pharma Revenue in Urinary System Drugs Business (2019-2024)
11.22.5 Astellas Pharma Recent Development
11.23 Dr. Dunner
11.23.1 Dr. Dunner Company Detail
11.23.2 Dr. Dunner Business Overview
11.23.3 Dr. Dunner Urinary System Drugs Introduction
11.23.4 Dr. Dunner Revenue in Urinary System Drugs Business (2019-2024)
11.23.5 Dr. Dunner Recent Development
11.24 Kowa
11.24.1 Kowa Company Detail
11.24.2 Kowa Business Overview
11.24.3 Kowa Urinary System Drugs Introduction
11.24.4 Kowa Revenue in Urinary System Drugs Business (2019-2024)
11.24.5 Kowa Recent Development
11.25 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
11.25.1 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Company Detail
11.25.2 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Business Overview
11.25.3 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Urinary System Drugs Introduction
11.25.4 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024)
11.25.5 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Recent Development
11.26 Tianjin Tongrentang Group
11.26.1 Tianjin Tongrentang Group Company Detail
11.26.2 Tianjin Tongrentang Group Business Overview
11.26.3 Tianjin Tongrentang Group Urinary System Drugs Introduction
11.26.4 Tianjin Tongrentang Group Revenue in Urinary System Drugs Business (2019-2024)
11.26.5 Tianjin Tongrentang Group Recent Development
11.27 Jiangsu Hengrui Pharmaceutical
11.27.1 Jiangsu Hengrui Pharmaceutical Company Detail
11.27.2 Jiangsu Hengrui Pharmaceutical Business Overview
11.27.3 Jiangsu Hengrui Pharmaceutical Urinary System Drugs Introduction
11.27.4 Jiangsu Hengrui Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024)
11.27.5 Jiangsu Hengrui Pharmaceutical Recent Development
11.28 Hunan Qianjin Xiang River Pharmaceutical
11.28.1 Hunan Qianjin Xiang River Pharmaceutical Company Detail
11.28.2 Hunan Qianjin Xiang River Pharmaceutical Business Overview
11.28.3 Hunan Qianjin Xiang River Pharmaceutical Urinary System Drugs Introduction
11.28.4 Hunan Qianjin Xiang River Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024)
11.28.5 Hunan Qianjin Xiang River Pharmaceutical Recent Development
11.29 Kunming Jida Pharmaceutical
11.29.1 Kunming Jida Pharmaceutical Company Detail
11.29.2 Kunming Jida Pharmaceutical Business Overview
11.29.3 Kunming Jida Pharmaceutical Urinary System Drugs Introduction
11.29.4 Kunming Jida Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024)
11.29.5 Kunming Jida Pharmaceutical Recent Development
11.30 Jiangsu Lianhuan Pharmaceutical
11.30.1 Jiangsu Lianhuan Pharmaceutical Company Detail
11.30.2 Jiangsu Lianhuan Pharmaceutical Business Overview
11.30.3 Jiangsu Lianhuan Pharmaceutical Urinary System Drugs Introduction
11.30.4 Jiangsu Lianhuan Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024)
11.30.5 Jiangsu Lianhuan Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Urinary System Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Injection
Table 3. Key Players of Tablets
Table 4. Key Players of Capsule
Table 5. Key Players of Suppository
Table 6. Key Players of Granules
Table 7. Key Players of Powder
Table 8. Key Players of Pills
Table 9. Key Players of Cream
Table 10. Key Players of Others
Table 11. Global Urinary System Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 12. Global Urinary System Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Urinary System Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Urinary System Drugs Market Share by Region (2019-2024)
Table 15. Global Urinary System Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Urinary System Drugs Market Share by Region (2025-2030)
Table 17. Urinary System Drugs Market Trends
Table 18. Urinary System Drugs Market Drivers
Table 19. Urinary System Drugs Market Challenges
Table 20. Urinary System Drugs Market Restraints
Table 21. Global Urinary System Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 22. Global Urinary System Drugs Market Share by Players (2019-2024)
Table 23. Global Top Urinary System Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urinary System Drugs as of 2023)
Table 24. Ranking of Global Top Urinary System Drugs Companies by Revenue (US$ Million) in 2023
Table 25. Global 5 Largest Players Market Share by Urinary System Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Urinary System Drugs Product Solution and Service
Table 28. Date of Enter into Urinary System Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Urinary System Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 31. Global Urinary System Drugs Revenue Market Share by Type (2019-2024)
Table 32. Global Urinary System Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 33. Global Urinary System Drugs Revenue Market Share by Type (2025-2030)
Table 34. Global Urinary System Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 35. Global Urinary System Drugs Revenue Market Share by Application (2019-2024)
Table 36. Global Urinary System Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 37. Global Urinary System Drugs Revenue Market Share by Application (2025-2030)
Table 38. North America Urinary System Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. North America Urinary System Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 40. North America Urinary System Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 41. Europe Urinary System Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Europe Urinary System Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Europe Urinary System Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Asia-Pacific Urinary System Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 45. Asia-Pacific Urinary System Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 46. Asia-Pacific Urinary System Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 47. Latin America Urinary System Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Latin America Urinary System Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 49. Latin America Urinary System Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 50. Middle East & Africa Urinary System Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 51. Middle East & Africa Urinary System Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 52. Middle East & Africa Urinary System Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 53. Johnson & Johnson Company Detail
Table 54. Johnson & Johnson Business Overview
Table 55. Johnson & Johnson Urinary System Drugs Product
Table 56. Johnson & Johnson Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 57. Johnson & Johnson Recent Development
Table 58. Bayer Company Detail
Table 59. Bayer Business Overview
Table 60. Bayer Urinary System Drugs Product
Table 61. Bayer Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 62. Bayer Recent Development
Table 63. Pfizer Company Detail
Table 64. Pfizer Business Overview
Table 65. Pfizer Urinary System Drugs Product
Table 66. Pfizer Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. GSK Company Detail
Table 69. GSK Business Overview
Table 70. GSK Urinary System Drugs Product
Table 71. GSK Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 72. GSK Recent Development
Table 73. Boehringer Ingelheim Company Detail
Table 74. Boehringer Ingelheim Business Overview
Table 75. Boehringer Ingelheim Urinary System Drugs Product
Table 76. Boehringer Ingelheim Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 77. Boehringer Ingelheim Recent Development
Table 78. Roche Company Detail
Table 79. Roche Business Overview
Table 80. Roche Urinary System Drugs Product
Table 81. Roche Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 82. Roche Recent Development
Table 83. Novartis Company Detail
Table 84. Novartis Business Overview
Table 85. Novartis Urinary System Drugs Product
Table 86. Novartis Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 87. Novartis Recent Development
Table 88. AstraZeneca Company Detail
Table 89. AstraZeneca Business Overview
Table 90. AstraZeneca Urinary System Drugs Product
Table 91. AstraZeneca Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 92. AstraZeneca Recent Development
Table 93. Dr. Reddy’s Laboratories Company Detail
Table 94. Dr. Reddy’s Laboratories Business Overview
Table 95. Dr. Reddy’s Laboratories Urinary System Drugs Product
Table 96. Dr. Reddy’s Laboratories Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 97. Dr. Reddy’s Laboratories Recent Development
Table 98. Mylan Company Detail
Table 99. Mylan Business Overview
Table 100. Mylan Urinary System Drugs Product
Table 101. Mylan Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 102. Mylan Recent Development
Table 103. Sun Pharma Company Detail
Table 104. Sun Pharma Business Overview
Table 105. Sun Pharma Urinary System Drugs Product
Table 106. Sun Pharma Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 107. Sun Pharma Recent Development
Table 108. Cipla Company Detail
Table 109. Cipla Business Overview
Table 110. Cipla Urinary System Drugs Product
Table 111. Cipla Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 112. Cipla Recent Development
Table 113. Merck Company Detail
Table 114. Merck Business Overview
Table 115. Merck Urinary System Drugs Product
Table 116. Merck Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 117. Merck Recent Development
Table 118. Cubist Pharmaceuticals Company Detail
Table 119. Cubist Pharmaceuticals Business Overview
Table 120. Cubist Pharmaceuticals Urinary System Drugs Product
Table 121. Cubist Pharmaceuticals Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 122. Cubist Pharmaceuticals Recent Development
Table 123. Abbott Laboratories Company Detail
Table 124. Abbott Laboratories Business Overview
Table 125. Abbott Laboratories Urinary System Drugs Product
Table 126. Abbott Laboratories Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 127. Abbott Laboratories Recent Development
Table 128. Eli Lilly Company Detail
Table 129. Eli Lilly Business Overview
Table 130. Eli Lilly Urinary System Drugs Product
Table 131. Eli Lilly Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 132. Eli Lilly Recent Development
Table 133. Melinta Therapeutics Company Detail
Table 134. Melinta Therapeutics Business Overview
Table 135. Melinta Therapeutics Urinary System Drugs Product
Table 136. Melinta Therapeutics Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 137. Melinta Therapeutics Recent Development
Table 138. Sanofi Company Detail
Table 139. Sanofi Business Overview
Table 140. Sanofi Urinary System Drugs Product
Table 141. Sanofi Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 142. Sanofi Recent Development
Table 143. Daiichi Sankyo Company Detail
Table 144. Daiichi Sankyo Business Overview
Table 145. Daiichi Sankyo Urinary System Drugs Product
Table 146. Daiichi Sankyo Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 147. Daiichi Sankyo Recent Development
Table 148. Lupin Company Detail
Table 149. Lupin Business Overview
Table 150. Lupin Urinary System Drugs Product
Table 151. Lupin Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 152. Lupin Recent Development
Table 153. Apogepha Company Detail
Table 154. Apogepha Business Overview
Table 155. Apogepha Urinary System Drugs Product
Table 156. Apogepha Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 157. Apogepha Recent Development
Table 158. Astellas Pharma Company Detail
Table 159. Astellas Pharma Business Overview
Table 160. Astellas Pharma Urinary System Drugs Product
Table 161. Astellas Pharma Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 162. Astellas Pharma Recent Development
Table 163. Dr. Dunner Company Detail
Table 164. Dr. Dunner Business Overview
Table 165. Dr. Dunner Urinary System Drugs Product
Table 166. Dr. Dunner Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 167. Dr. Dunner Recent Development
Table 168. Kowa Company Detail
Table 169. Kowa Business Overview
Table 170. Kowa Urinary System Drugs Product
Table 171. Kowa Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 172. Kowa Recent Development
Table 173. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Company Detail
Table 174. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Business Overview
Table 175. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Urinary System Drugs Product
Table 176. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 177. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Recent Development
Table 178. Tianjin Tongrentang Group Company Detail
Table 179. Tianjin Tongrentang Group Business Overview
Table 180. Tianjin Tongrentang Group Urinary System Drugs Product
Table 181. Tianjin Tongrentang Group Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 182. Tianjin Tongrentang Group Recent Development
Table 183. Jiangsu Hengrui Pharmaceutical Company Detail
Table 184. Jiangsu Hengrui Pharmaceutical Business Overview
Table 185. Jiangsu Hengrui Pharmaceutical Urinary System Drugs Product
Table 186. Jiangsu Hengrui Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 187. Jiangsu Hengrui Pharmaceutical Recent Development
Table 188. Hunan Qianjin Xiang River Pharmaceutical Company Detail
Table 189. Hunan Qianjin Xiang River Pharmaceutical Business Overview
Table 190. Hunan Qianjin Xiang River Pharmaceutical Urinary System Drugs Product
Table 191. Hunan Qianjin Xiang River Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 192. Hunan Qianjin Xiang River Pharmaceutical Recent Development
Table 193. Kunming Jida Pharmaceutical Company Detail
Table 194. Kunming Jida Pharmaceutical Business Overview
Table 195. Kunming Jida Pharmaceutical Urinary System Drugs Product
Table 196. Kunming Jida Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 197. Kunming Jida Pharmaceutical Recent Development
Table 198. Jiangsu Lianhuan Pharmaceutical Company Detail
Table 199. Jiangsu Lianhuan Pharmaceutical Business Overview
Table 200. Jiangsu Lianhuan Pharmaceutical Urinary System Drugs Product
Table 201. Jiangsu Lianhuan Pharmaceutical Revenue in Urinary System Drugs Business (2019-2024) & (US$ Million)
Table 202. Jiangsu Lianhuan Pharmaceutical Recent Development
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Urinary System Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Urinary System Drugs Market Share by Type: 2023 VS 2030
Figure 3. Injection Features
Figure 4. Tablets Features
Figure 5. Capsule Features
Figure 6. Suppository Features
Figure 7. Granules Features
Figure 8. Powder Features
Figure 9. Pills Features
Figure 10. Cream Features
Figure 11. Others Features
Figure 12. Global Urinary System Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 13. Global Urinary System Drugs Market Share by Application: 2023 VS 2030
Figure 14. Kidney Disease Medication Case Studies
Figure 15. Medication For Prostate Disease Case Studies
Figure 16. Male Dysfunction Case Studies
Figure 17. Lithotripsy Drug Case Studies
Figure 18. Others Case Studies
Figure 19. Urinary System Drugs Report Years Considered
Figure 20. Global Urinary System Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 21. Global Urinary System Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 22. Global Urinary System Drugs Market Share by Region: 2023 VS 2030
Figure 23. Global Urinary System Drugs Market Share by Players in 2023
Figure 24. Global Top Urinary System Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urinary System Drugs as of 2023)
Figure 25. The Top 10 and 5 Players Market Share by Urinary System Drugs Revenue in 2023
Figure 26. North America Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. North America Urinary System Drugs Market Share by Country (2019-2030)
Figure 28. United States Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Canada Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Europe Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Europe Urinary System Drugs Market Share by Country (2019-2030)
Figure 32. Germany Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. France Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. U.K. Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Italy Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Russia Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Nordic Countries Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Asia-Pacific Urinary System Drugs Market Share by Region (2019-2030)
Figure 40. China Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Japan Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. South Korea Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Latin America Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Latin America Urinary System Drugs Market Share by Country (2019-2030)
Figure 48. Mexico Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Brazil Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Urinary System Drugs Market Share by Country (2019-2030)
Figure 52. Turkey Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Urinary System Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Johnson & Johnson Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 55. Bayer Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 56. Pfizer Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 57. GSK Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 58. Boehringer Ingelheim Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 59. Roche Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 60. Novartis Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 61. AstraZeneca Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 62. Dr. Reddy’s Laboratories Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 63. Mylan Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 64. Sun Pharma Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 65. Cipla Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 66. Merck Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 67. Cubist Pharmaceuticals Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 68. Abbott Laboratories Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 69. Eli Lilly Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 70. Melinta Therapeutics Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 71. Sanofi Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 72. Daiichi Sankyo Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 73. Lupin Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 74. Apogepha Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 75. Astellas Pharma Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 76. Dr. Dunner Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 77. Kowa Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 78. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 79. Tianjin Tongrentang Group Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 80. Jiangsu Hengrui Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 81. Hunan Qianjin Xiang River Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 82. Kunming Jida Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 83. Jiangsu Lianhuan Pharmaceutical Revenue Growth Rate in Urinary System Drugs Business (2019-2024)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
